ChartRow logo
Data provided bySource: Twelve Data
ASND
$271.19-0.20%
as of close, Nov 17, 2026
☾ AH $271.19 -0.20%
Share this page

ASND — Ascendis Pharma A/S Ordinary Share price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in ASND be worth today? →
ASND returns: By year · By month · By week · Trailing

Price data

Price
$271.19
YTD price return
+27.18%
YTD total return
+27.18%
Market cap
16.8B
Enterprise value
17.3B
Shares outstanding
62M
52W low
$188.08
52W high
$282.15
From 52W high
-3.88%
From 52W low
+44.19%
52W range
88%$188–$282
Beta
0.33

Volume

Rel volume
0.82×
30D volume
713K
30D $ vol
175.6M

Insider trading

Insider net 1W
none
Insider net 1M
none
Insider net 3M
−$873K
Insider net 1Y
−$4.7M

Form 4 transactions by trade date, as filed; latest on file 2026-09-08.

Fundamentals

Sales (ttm)
814.9M
Sales/share
$13.15
EPS (ttm)
-$4.25
Book value/share
-$3.09
Net margin
-31.67%
ROA
-16.85%
Current ratio
1.04

Growth (CAGR, ttm) · 10Y

Sales
+107.26%+147.31%+152.61%+56.89%
Shares
+2.12%+2.74%+2.89%+10.06%

Per-share growth (CAGR, ttm) · 10Y

Sales/share
+102.95%+140.72%+145.51%+42.56%
Price
+25.25%+41.85%+11.85%+29.81%
Total return
+25.25%+41.85%+11.85%+29.81%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
-63.7×
Fwd P/E
22.4×
P/S (ttm)
20.6×
P/B (mrq)
-87.8×
EV/Sales (ttm)
21.3×
Buyback yield (realized, 1y)
-2.12%
Shareholder yield (realized, 1y)
-2.12%
Buyback yield (cash, ttm)
0.12%
Shareholder yield (cash, ttm)
0.12%

Vs own 10Y history

P/S
9th
P/B
100th

Bar = where today’s multiple sits in ASND’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-17#

Data provided bySource: Twelve Data
1D
-0.20%
5D
+5.69%
1M
+20.40%
3M
+9.62%
YTD
+27.18%
1Y
+25.23%
5Y
+75.01%
1D
-0.20%
5D
+5.69%
1M
+20.40%
3M
+9.62%
YTD
+27.18%
1Y
+25.23%
5Y
+75.01%

Fundamentals#

Revenue

5Y CAGR +152.6%10Y CAGR +56.9%
$814.9M FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Operating income

5Y n/m5Y n/m
— FY25
FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

EPS (diluted)

10Y n/m
−$4.25 FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Free cash flow

5Y n/m5Y n/m
— FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

FY25: operating cash flow $61M, capex —

No quarters filed for this figure.

Shares (diluted)

10Y +155.0%
60.6M FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Net income

5Y n/m10Y n/m
−$258M FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Full ASND financials →

Ascendis Pharma A/S is a global biopharmaceutical company focused on developing and commercializing therapies for rare endocrine diseases and other serious chronic conditions. The company uses its proprietary TransCon technology platform to create medicines designed to improve treatment delivery and address unmet medical needs. Its current portfolio includes marketed products for growth hormone deficiency and chronic hypoparathyroidism, along with clinical-stage programs in endocrinology rare disease and oncology. Headquartered in Copenhagen, Denmark, Ascendis Pharma operates across Europe and the United States, combining research, development, and commercialization capabilities to support patients, physicians, and healthcare systems in specialized therapeutic areas.

Hellerup, Denmark·1,189 employees·Biotechnology·ascendispharma.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding ASND#

12 of the 193 ETFs ChartRow carries live hold ASND. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
IBBiShares Biotechnology ETF1.3%
IWPiShares Russell Mid-Cap Growth ETF0.3%
IWRiShares Russell Midcap ETF0.1%
IWFiShares Russell 1000 Growth ETF0.0%
VONGVanguard Russell 1000 Growth ETF0.0%
ONEQFidelity Nasdaq Composite Index ETF0.0%
IWBiShares Russell 1000 ETF0.0%
VONEVanguard Russell 1000 ETF0.0%
TickerName1M1D
LLYEli Lilly and Company+12.61%-1.13%
JNJJohnson & Johnson+9.05%-1.36%
ABBVAbbVie Inc.+2.59%-0.59%
MRKMerck & Co. Inc.-1.77%-0.75%
UNHUnitedHealth Group Incorporated Common Stock (DE)-2.93%-5.42%
NVSNovartis AG+5.65%-0.67%
TMOThermo Fisher Scientific Inc.-0.47%-0.66%
AMGNAmgen Inc.+5.88%-0.95%